Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo drug aims to tackle high cholesterol in one daily pill

NCT ID NCT03527069

First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 28 times

Summary

This Phase 3 trial tested a new combination drug called Cipros 10 against the standard statin Crestor in 146 adults with dyslipidemia (high cholesterol and triglycerides). The goal was to see if Cipros 10 could lower triglyceride levels more effectively. Participants took one pill daily, and researchers tracked both lab results and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Allergisa

    Campinas, São Paulo, Brazil

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cipros 10 (a combination drug containing rosuvastatin and other agents)

What this could lead to

If successful, this could offer a new once-daily pill option to help control high triglycerides and cholesterol.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than existing statins like Crestor, and side effects are possible.

Conditions

The condition(s) this trial relates to.

Dyslipidemias hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.